A feasibility study of concurrent chemotherapy using S-1 with stereotactic body radiation therapy for clinical stage I-IIA Non-small Cell Lung Cancer (LOGIK1602)

A feasibility study of concurrent chemotherapy using S-1 with stereotactic body radiation therapy for clinical stage I-IIA Non-small Cell Lung Cancer (LOGIK1602) - A feasibility study of concurrent chemotherapy using S-1 with stereotactic body radiation therapy for clinical stage I-IIA Non-small Cell Lung Cancer (LOGIK1602)

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000032693

Enrollment

Registered

2018-06-01

Start date

2018-06-11

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non-small cell lung cancer

Interventions

S-1 80 mg/m2 (daily oral administration) for 2 weeks with stereotactic body radiation therapy 48 Gy/ 4 fractions

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Histologically or transbronchoscopic cytologically or Clinically(exe. FDG-PET) confirmed non-small cell lung cancer 2.StageI-IIA(T1-2b, N0, M0) with images 3.No prior therapy for the disease 4.Aged 20<= years 5.ECOG performance status of 0-2 6.Required baseline laboratory parameters (within 2 weeks before registration): 1)PaO2 >= 60Torr 2)FEV1.0 >= 700 ml 3)Neu >= 1,500/ mm3 4)Hb >= 10g/dl 5)Plt >= 100,000/ mm3 6)AST < 100IU/ml 7)ALT < 100IU/ml 8)T-Bil <= 2.0mg/dl 9)Cre <= 1.5mg/dl 10)Creatinine Clearance >= 60ml/min 11)Written informed consent

Exclusion criteria

Exclusion criteria: 1.Apparent interstitial pneumonitis and fibrosis 2.Active inflammation without oral drugs 3.Double cancer 4.Pregnancy 5.Psychiatric disorder 6.Steroid administration 7.Oxygen administration 8.Fever of 38.0 degrees centigrade or higher

Design outcomes

Primary

Measure	Time frame
Completion Rate of S-1 administration & radiotherapy	—

Secondary

Measure	Time frame
Adverse events, Grade 2 or greater radiation pneumonitis,Overall survival rate at 2 years, Disease-free survival rate at 2 years, Local control rate at 2 years	—

Countries

Japan

Contacts

Public ContactTomonari Sasaki

Graduate School of Medical Sciences, Kyushu University Division of Quantum Radiation Sciences, Department of Health Sciences

tomonari@hs.med.kyushu-u.ac.jp092-642-6726

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026